Early clinical experience with the ACCERO ^® heal stent for the treatment of intracranial aneuyrsms

PurposeTo evaluate the safety, technical performance, and short-term efficacy of the ACCERO^® heal stent for stent-assisted coil embolization in the treatment of intracranial aneurysms.MethodsWe retrospectively analyzed 32 consecutive patients with intracranial aneurysms treated with the ACCERO^® heal stent at two German centers between September 2021 and December 2023. Data were collected on patient demographics, aneurysm characteristics, procedural technique, and complications. Aneurysm occlusion was classified using the Modified Raymond-Roy Classification (MRRC), and stent wall apposition was assessed qualitatively. Follow-up imaging was analyzed for recurrence and in-stent stenosis.ResultsA total of 34 ACCERO^® heal stents were implanted in 32 patients (median age 54 years; 87.5% female). Optimal wall apposition was achieved in all cases. Immediate complete occlusion (MRRC I) was observed in 87.5%. Periprocedural complications occurred in five patients (15.6%), including one death and one non-fatal stroke in the context of ruptured aneurysms. Intraoperative in-stent thrombosis occurred in two cases (6.3%), both resolving without clinical sequelae. At follow-up, six patients (19.3%) had aneurysm recurrence or residual, and three (9.7%) required retreatment. In-stent stenosis occurred in three patients (9.7%) and resolved with conservative management.ConclusionThe ACCERO^® heal stent is a reliable and effective option for stent-assisted coiling of intracranial aneurysms. Its low-profile design and HEAL antithrombogenic coating support precise deployment and favorable early clinical outcomes. Prospective studies are needed to confirm these findings.